Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | SGK1 | O00141 | 3/20 | 0.42 |
| ▸ | CCR2 | P41597 | 4/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5615200 | 0.88 | GSPT1 (0.47) | BRD4NR1I2GHSR | |
| SCHEMBL1809299 | 0.82 | PTGDR2 (0.47) | BRD4 | |
| SCHEMBL1815199 | 0.81 | SLC22A12 (0.53) | BRD4SLC22A12 | |
| SCHEMBL1814225 | 0.81 | PTGDR2 (0.46) | BRD4NR1I2KIT | |
| SCHEMBL4370085 | 0.76 | ALOX15 (0.42) | BRD4NR1I2 | |
| SCHEMBL1821354 | 0.73 | BRD4 (0.59) | BRD4ACLYSGK1PGR | |
| SCHEMBL1811117 | 0.73 | ACLY (0.47) | BRD4ACLYPTGES2CCR2NR1I2 | |
| SCHEMBL3903016 | 0.72 | NR1I2 (0.48) | BRD4NR1I2 | |
| SCHEMBL3906452 | 0.72 | ACLY (0.54) | BRD4ACLYPTGES2CCR2KIT | |
| SCHEMBL5615658 | 0.71 | ACLY (0.44) | BRD4ACLYCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | BRD4 2606/4885ACLY 2238/4885PTGES2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.